Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma.
about
The hedgehog pathway in triple-negative breast cancerCancer of the Pancreas: Molecular Pathways and Current Advancement in TreatmentAnti-Cancer Stem-like Cell Compounds in Clinical Development - An Overview and Critical AppraisalTargeting stromal microenvironment in pancreatic ductal adenocarcinoma: controversies and promisesHedgehog signaling: modulation of cancer properies and tumor mircroenvironmentMolecular targets for the treatment of pancreatic cancer: Clinical and experimental studiesIndividualized treatment of gastric cancer: Impact of molecular biology and pathohistological featuresClinical Implications of Hedgehog Pathway Signaling in Prostate CancerPancreatic cancer: optimizing treatment options, new, and emerging targeted therapiesCooperative integration between HEDGEHOG-GLI signalling and other oncogenic pathways: implications for cancer therapyConcise Review: Stem Cells in Pancreatic Cancer: From Concept to TranslationThe Use of Gene Ontology Term and KEGG Pathway Enrichment for Analysis of Drug Half-LifeOrmeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancerRandomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer.CASTIN: a system for comprehensive analysis of cancer-stromal interactome.Codelivery of small molecule hedgehog inhibitor and miRNA for treating pancreatic cancerMicelle Mixtures for Coadministration of Gemcitabine and GDC-0449 To Treat Pancreatic Cancer.Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy.Bufalin suppresses cancer stem-like cells in gemcitabine-resistant pancreatic cancer cells via Hedgehog signaling.Cisplatin induces stemness in ovarian cancer.HER2 expression identifies dynamic functional states within circulating breast cancer cells.Tris DBA palladium is highly effective against growth and metastasis of pancreatic cancer in an orthotopic model.Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer.Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models.SHH inhibitors for the treatment of medulloblastoma.Stromal SPOCK1 supports invasive pancreatic cancer growth.Reduced proliferation and colony formation of head and neck squamous cell carcinoma (HNSCC) after dual targeting of EGFR and hedgehog pathways.Cancer cell chemokines direct chemotaxis of activated stellate cells in pancreatic ductal adenocarcinoma.Hedgehog pathway overexpression in pancreatic cancer is abrogated by new-generation taxoid SB-T-1216.Nicotine induces self-renewal of pancreatic cancer stem cells via neurotransmitter-driven activation of sonic hedgehog signalling.A novel therapeutic approach against B-cell non-Hodgkin's lymphoma through co-inhibition of Hedgehog signaling pathway and autophagy.Inhibition of the CyclinD1 promoter in response to sonic hedgehog signaling pathway transduction is mediated by Gli1The role of stromal cancer-associated fibroblasts in pancreatic cancer.Inhibition of Pancreatic Cancer Cell-Induced Paracrine Hedgehog Signaling by Liver X Receptor Agonists and Oxy16, a Naturally Occurring Oxysterol.SHh-Gli1 signaling pathway promotes cell survival by mediating baculoviral IAP repeat-containing 3 (BIRC3) gene in pancreatic cancer cells.MicroRNA-199a and -214 as potential therapeutic targets in pancreatic stellate cells in pancreatic tumor.Hedgehog-mesenchyme gene signature identifies bi-modal prognosis in luminal and basal breast cancer sub-types.Comment on: α-smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study.Reviewing the Utility of EUS FNA to Advance Precision Medicine in Pancreatic Cancer.Tumor-stroma IL-1β-IRAK4 feedforward circuitry drives tumor fibrosis, chemoresistance, and poor prognosis in pancreatic cancer.
P2860
Q26740373-E57D5096-B55C-4E43-88FD-5C87B66122A7Q26740619-AF776C91-402F-41A5-BD58-40D6C2452991Q26744536-C1FD02AC-7B24-41E6-8269-18C3EDD882A1Q26747140-C118AB58-9E75-47CB-8297-E8648000E927Q26764740-C7DDC5CA-DC82-456E-A715-FAC47D2725F6Q26774636-351E9166-49DB-46B5-BC2A-F66DC7C2780CQ26776198-975938AE-73F2-425A-80A0-619E91903864Q26783028-44C89D90-FDBE-41C4-9185-9936999E575AQ26799714-F61D19D4-992E-42D8-9548-ED1A4E853274Q26865136-96EC4874-9018-42CE-BEB5-35AFB77A4EEFQ28081553-C188A132-EA28-4C95-9CFF-BC82DB4A10C2Q28552953-7CD4BDB0-1B8E-40D9-B14B-B3C8EA14FE5DQ35674826-38ADC704-2117-4DDC-B8C6-00978EC17B35Q35830110-F08D2043-2BEE-4F55-B946-BC8A40EF5685Q36187726-D3AFD7BA-B0A9-41E9-A9C7-4471CA8EDA44Q36791689-50068F71-8D19-4058-923F-84FE297A033CQ36984038-72798891-6685-4289-BED2-A481C25E8A97Q37176648-A4450C3D-FCB9-48E8-B4FC-F0D2B5DBAAFDQ37190831-B6CA5335-7BC3-4E53-A20A-CC8A1A91E7A0Q37327524-40333882-387A-4B45-98F0-311312FA20A7Q37510512-DE9BB365-14F7-4634-B506-FB9D6C7A6001Q37588325-A9E12C25-ED20-4CC4-A268-9FF56E74526AQ37683769-0EDF9993-3C60-4529-B4D5-1B67078DFC83Q37706198-5369C17D-4244-4BFB-9E0D-A8D323A1DD47Q38509205-1C359E73-0169-42E1-A524-8CCA31EBA50CQ38685933-68D5612D-337D-4D49-98F8-5FB2A3B644F5Q38720111-C0F6BE44-1FCE-4B29-828D-E0CA284E6332Q38721161-45F879CA-C168-4643-80A1-CB3C0CE7F3B3Q38749227-7B97B4B3-C63E-4532-BCD5-7D490F8921A0Q38810062-C078B80D-E14A-4B2A-B6DB-A14711C251F5Q38811800-8DC3546E-466E-4679-B184-227608597CF5Q38998667-B1521CCE-182B-48F7-A15F-7EC9A7079776Q39205210-8646E163-BA09-4DD1-95B0-B2C2C47E4FA6Q39525476-FD7BB10E-E550-46E2-8262-F8D6E4B80CBBQ40056036-C6BB9E79-8055-406B-8CD5-5042F144A0A9Q42425474-9B195372-E06E-4F6C-973C-B6A0C92E6B26Q42516893-A604B0E4-E60B-4D54-A3EB-F9DC0CBD321FQ43172015-62083B3B-CC20-4576-BCBC-9957047C2A85Q49576059-3E1E08D7-552E-41FD-AEC5-65BBD6724E87Q49832519-A4E3DF55-8D58-4B4C-9EA3-04A9995F177F
P2860
Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Pilot clinical trial of hedgeh ...... tic pancreatic adenocarcinoma.
@ast
Pilot clinical trial of hedgeh ...... tic pancreatic adenocarcinoma.
@en
Pilot clinical trial of hedgehog pathway inhibitor GDC-0449
@nl
type
label
Pilot clinical trial of hedgeh ...... tic pancreatic adenocarcinoma.
@ast
Pilot clinical trial of hedgeh ...... tic pancreatic adenocarcinoma.
@en
Pilot clinical trial of hedgehog pathway inhibitor GDC-0449
@nl
prefLabel
Pilot clinical trial of hedgeh ...... tic pancreatic adenocarcinoma.
@ast
Pilot clinical trial of hedgeh ...... tic pancreatic adenocarcinoma.
@en
Pilot clinical trial of hedgehog pathway inhibitor GDC-0449
@nl
P2093
P2860
P1476
Pilot clinical trial of hedgeh ...... tic pancreatic adenocarcinoma.
@en
P2093
Diane M Simeone
Edward J Kim
Ethan V Abel
Gazala N Khan
Joel K Greenson
John L Blau
Kent A Griffith
Mark M Zalupski
Naoko Takebe
Ronald Craig
P2860
P304
P356
10.1158/1078-0432.CCR-14-1269
P407
P577
2014-10-02T00:00:00Z